

## YONSA (abiraterone acetate)

### **Pre - PA Allowance**

None

\_\_\_\_\_

## **Prior-Approval Requirements**

Age 18 years of age or older

**Gender** Male

**Diagnosis** 

Patient must have the following:

Metastatic castration resistant prostate cancer (CRPC)

#### AND ALL of the following:

- 1. Used in combination with methylprednisolone
- 2. **NO** dual therapy with another androgen receptor inhibitor (see Appendix 1)
- 3. Prescriber agrees to advise males with female partners of reproductive potential to use effective contraception during treatment and for 3 weeks after the last dose of Yonsa

## **Prior - Approval Limits**

Quantity

| Strength | Quantity                |
|----------|-------------------------|
| 125 mg   | 360 tablets per 90 days |

**Duration** 12 months

Prior – Approval *Renewal* Requirements

Same as above

Prior - Approval Renewal Limits

Same as above



# YONSA (abiraterone acetate)

## **Appendix 1 - List of Androgen Receptor Inhibitors**

| Generic Name          | Brand Name |
|-----------------------|------------|
| abiraterone           | Yonsa      |
| abiraterone           | Zytiga     |
| abiraterone/niraparib | Akeega     |
| apalutamide           | Erleada    |
| darolutamide          | Nubeqa     |
| enzalutamide          | Xtandi     |
| nilutamide            | Nilandron  |